Portfolio Companies News
April 6, 2020Orexo ends share buy-back program
Uppsala, Sweden – April 6, 2020. Orexo AB (publ) has ended the program to repurchase its own ordinary shares that was announced on February 17, 2020. A total of 500,000 shares, equivalent to approximately 1.4 per cent of the issued ordinary shares in the company, have been repurchased as p... read more
April 6, 2020GenSight Biologics Provides Update ...
Paris, France, April 6, 2020, 7.30 am CET – GenSight Biologics (Euronext : SIGHT, ISIN : FR0013183985, PEA-PME eligible), a biopharma company focused on discovering and developing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, toda... read more
April 3, 2020BONESUPPORT HOLDING AB (publ) publi...
Lund, Sweden, 15:00 CET, 3 April 2020 – BONESUPPORT HOLDING AB (publ), an emerging leader in orthobiologics for the management of bone injuries, publishes its annual report for 2019 and announces that the outbreak of COVID-19 will have a financial impact on the company during the fir... read more
April 2, 2020Oncopeptides strengthens its corpor...
STOCKHOLM — April 2, 2020 — Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today that Rolf Gulliksen has been appointed global head of corporate communications. Rolf has 30 years of experience from senior corporate communications roles in the life science industry and consultancy. ... read more
April 1, 2020Nordic Nanovector Announces Focus o...
Oslo, Norway, 1 April 2020 Nordic Nanovector ASA (OSE: NANO) today announces a number of initiatives to speed up recruitment into its pivotal Phase 2b PARADIGME trial with Betalutin® in advanced follicular lymphoma (FL) as well as to extend its cash runway into 2021. A webcast will take ... read more
February 19, 2020Q4 2019 General Market Overview
Since the start in 1996, HealthCap funds have invested in 115 portfolio companies.
43 of the portfolio companies have been taken public on nine different markets.
25 of the portfolio companies’ pharmaceutical products have been approved for marketing.
Since the start in 1996, HealthCap has helped build 7 companies with a valuation of USD 1 billion or more and 35 companies with a valuation of SEK 1 billion or more.